PITTSBURGH, April 2, 2025 -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of RxARECONCIERGE™, a new patient support model to improve access, logistics, and coordination of care for people taking cell and gene therapies (CGTs).
PANTHERx developed its RxARECONCIERGE™ personalized patient and provider care approach specifically to address the unique requirements of CGTs: highly personalized access and reimbursement support services; ultra-low-temperature storage; just-in-time dispensing and fulfillment to treatment centers; education and support for the people taking CGTs and the healthcare professionals (HCPs) who prescribe them; long-term follow-up of patient-reported outcomes; and actionable insights for manufacturers of CGT.
"Since our founding in 2011, PANTHERx has excelled in helping patients and HCPs navigate the complexities of rare disease treatments, making the expansion to cell and gene therapies a natural progression," said Bansi Nagji, PANTHERx Rare CEO. "Our RxARECONCIERGE™ model delivers truly coordinated care, offering a flexible, customized approach that aligns with the needs of patients, prescribers, treatment centers, insurers, and the manufacturers of cell and gene therapies."
About PANTHERx Rare
PANTHERx Rare is a specialty pharmacy exclusively focused on rare and orphan diseases, distributing therapies and providing access and support services to those needing them most. Known as The Rare Disease Pharmacy®, PANTHERx transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to people living with rare and devastating conditions.
PANTHERx is a dual-accredited specialty pharmacy, holding distinctions in rare disease including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence. As a pharmacy focused on patient satisfaction, PANTHERx is the seven-time winner of the prestigious MMIT Patient Choice Award, including the 2024 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania and is licensed in all 50 states and U.S. territories.
About cell and gene therapies (CGT)
CGTs are among the next wave of medical innovation based on scientists' understanding of the human genome. According to the research firm Evaluate, 86% of the CGT pipeline is to treat orphan diseases,1 and the National Organization for Rare Disorders (NORD) noted that "…[G]ene therapies offer patients a better chance at long-term improvements in how their bodies function and their quality of life."2
CONTACT
For more information, please contact marketing@pantherxrare.com.
1. Internal analysis of Evaluate's 2025 "Pipeline" data.
2. National Organization for Rare Disorders, "Gene Therapy," accessed March 25, 2025. https://rarediseases.org/gene-therapy/
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
